Tamoxifentherapie-begleitende CYP2D6-Testung: Outline zum aktuellen wissenschaftlichen Kenntnisstand // Tamoxifen-therapy and CYP2D6-Testing: The State of Knowledge

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal für Reproduktionsmedizin und Endokrinologie - Journal of Reproductive Medicine and Endocrinology

• Publication date

  2017-07-18

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacogenomics and Personalized Medicine

  2020cited by this paper
• Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.

  2016cited by this paper
• Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial

  2016cited by this paper
• The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity

  2015cited by this paper
• Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

  2015cited by this paper
• CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects

  2015cited by this paper
• Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.

  2014influential reference
• Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

  2014cited by this paper
• Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy

  2014cited by this paper
• Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.

  2014cited by this paper
• Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen.

  2014cited by this paper
• Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.

  2014cited by this paper
• Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer

  2014cited by this paper
• Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

  2013influential reference
• CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer.

  2013cited by this paper
• CYP2D6 Genotype and Tamoxifen Activity: Understanding Interstudy Variability in Methodological Quality

  2013influential reference
• CYP2D6 Genotype and Tamoxifen Response for Breast Cancer: A Systematic Review and Meta-Analysis

  2013cited by this paper
• Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

  2013cited by this paper
• Relationship between Genotypes Sult1a2 and Cyp2d6 and Tamoxifen Metabolism in Breast Cancer Patients

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumours

  2013cited by this paper
• CYP2D6 Genotype Should Not Be Used to Determine Endocrine Therapy in Postmenopausal Breast Cancer Patients

  2013cited by this paper
• CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations

  2013cited by this paper
• Reply to A.-S. Dieudonné et al and J.M. Rae et al.

  2013cited by this paper
• CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial

  2013cited by this paper
• CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8

  2012cited by this paper
• Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial

  2012cited by this paper
• Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

  2012cited by this paper
• CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

  2012influential reference
• Endoxifen Levels and Its Association With CYP2D6 Genotype and Phenotype: Evaluation of a Southern Brazilian Population Under Tamoxifen Pharmacotherapy

  2012cited by this paper
• The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

  2012cited by this paper
• Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

  2012cited by this paper
• Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy

  2012cited by this paper
• Tamoxifen and CYP2D6: a contradiction of data.

  2012cited by this paper
• CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

  2012influential reference
• CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark

  2011cited by this paper
• Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.

  2011cited by this paper
• Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes

  2011cited by this paper
• Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients

  2011cited by this paper
• CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification

  2010cited by this paper
• Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy

  2010cited by this paper
• Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

  2010cited by this paper
• CYP2D6 testing to predict response to tamoxifen in women with breast cancer. Pharmacogenomic.

  2010influential reference
• The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users

  2009cited by this paper
• Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

  2009cited by this paper
• No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment.

  2009cited by this paper
• Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response

  2008cited by this paper
• Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.

  2008cited by this paper
• Differential patterns of allelic loss in estrogen receptor‐positive infiltrating lobular and ductal breast cancer

  2008cited by this paper
• Impact of CYP2D6*10 on recurrence‐free survival in breast cancer patients receiving adjuvant tamoxifen therapy

  2008cited by this paper
• Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

  2007cited by this paper
• The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

  2006cited by this paper
• Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial.

  2006cited by this paper
• Chromosome 22 array-CGH profiling of breast cancer delimited minimal common regions of genomic imbalances and revealed frequent intra-tumoral genetic heterogeneity.

  2006cited by this paper
• Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

  2005cited by this paper
• Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

  2005cited by this paper
• Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

  2003cited by this paper

• No citing papers are available for this paper.